SCHEMBL6363594

SCHEMBL6363594

O=c1nc[nH]c2cnccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.53
KDM4A O75164 1/20 0.53
KDM4B O94953 1/20 0.53
KDM5C P41229 1/20 0.53
KDM5B Q9UGL1 1/20 0.53
KDM3A Q9Y4C1 1/20 0.53
DYRK1A Q13627 10/20 0.44
NFATC1 O95644 6/20 0.44
GSK3B P49841 4/20 0.44
PARP1 P09874 2/20 0.43
PDPK1 O15530 1/20 0.42
TGFBR1 P36897 1/20 0.42
IKBKE Q14164 1/20 0.42
KDM5A P29375 2/20 0.42
CDK2 P24941 2/20 0.41
DYRK1B Q9Y463 2/20 0.41
IGF1R P08069 1/20 0.41
CHUK O15111 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GABRP O00591 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402056 0.85 KDM4C (0.49) KDM4CKDM4AKDM4BKDM5CKDM5B
SCHEMBL6836405 0.77 DYRK1A (0.44) KDM4CKDM4AKDM4BKDM5CKDM5B
Quinazolinone SCHEMBL10418 0.74 PARP1 (0.48) DYRK1AGSK3BPARP1PDPK1IKBKE
Quinazolinone SCHEMBL7746268 0.72 PARP1 (0.47) DYRK1AGSK3BPARP1PDPK1IKBKE
Quinazolinone SCHEMBL28241793 0.72 PARP1 (0.47) DYRK1AGSK3BPARP1PDPK1IKBKE
Quinazolinone SCHEMBL8201415 0.72 PARP1 (0.47) DYRK1AGSK3BPARP1PDPK1IKBKE
SCHEMBL89868 0.71
SCHEMBL29837279 0.71
SCHEMBL5144248 0.71 ALDH1A1 (0.48) KDM4CKDM4AKDM4BKDM5CKDM5B
Quinazolinone SCHEMBL7744396 0.71 PARP1 (0.46) DYRK1AGSK3BPARP1PDPK1IKBKE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3430008-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-05-18 EP claimed
US-10208039-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-19 US claimed
EP-3430008-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2019-01-23 EP claimed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 US claimed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 US claimed
WO-2017161012-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-09-21 WO claimed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 US claimed
EP-0733633-A1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-09-25 EP claimed
US-11957683-B2 Bicyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-16 US disclosed
US-20230382909-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-30 US disclosed
EP-3600287-B1 INHIBITORS OF KINASE NETWORKS AND USES THEREOF PURDUE RESEARCH FOUNDATION (US) 2023-07-05 EP disclosed
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO PHARMA (FR) 2023-05-18 US disclosed
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-04-20 US disclosed
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-04-20 US disclosed
EP-0912572-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LTD (GB) 2003-01-15 EP disclosed
US-6207669-B1 IN TREATMENT OF CANCER AND PSORIASIS GLAXO WELLCOME INC. 2001-03-27 US disclosed
EP-0912572-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 EP disclosed
WO-1998002437-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 WO disclosed
EP-0742717-A1 BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1996-11-20 EP disclosed
EP-0733633-A1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER NQO2, NQO1, NDUFV2 KDM4C 1137/4885KDM4A 1448/4885KDM4B 1297/4885
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4A 11/4885KDM4B 21/4885
US-10030017-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4A 11/4885KDM4B 21/4885
US-20230382909-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 KDM4C 3666/4885KDM4A 4733/4885KDM4B 4384/4885
US-11957683-B2 Bicyclic compounds SLC10A1, PKD1, CYP11B2 KDM4C 3666/4885KDM4A 4733/4885KDM4B 4384/4885
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4A 11/4885KDM4B 21/4885
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C KDM4C 9/4885KDM4A 11/4885KDM4B 21/4885
US-10208039-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4A 11/4885KDM4B 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.